Lucas from Germany

Registered at the short selling broker Skilling, 4 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

AlloVir, Inc. (ALVR) shares information

AlloVir Inc


24h Change

-0.47 %

ALVR

Live rate: Market closed

Stock data per Wednesday 14 Apr, 2021

ALVR
NASDAQ/NGS (GLOBAL SELECT MARKET)
23.67
23.53
23.56
-0.11 (-0.47%)
US Market is closed

Live Stock price in graph for AlloVir Inc (ALVR)

  • Latest Volume

    288,801 (30.61 %)

  • Volume prev. day

    221,124

  • Avg. daily volume

    560,389

  • Market cap

    1,533,917,928

  • P/E ratio

    n/a

  • Today high

    25 USD

  • Today low

    23 USD

  • 52 week high

    48.96 USD

  • 52 week low

    18.15 USD

  • YTD Change

    n/a

Quick links

 

Latest news about AlloVir Inc

Below you can find the most recent news posts about AlloVir Inc, primarily from US and UK based news sources.

The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO

Tuesday, 23 March 2021, 09:18:00
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 22) …
— Benzinga


AlloVir Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021

Monday, 22 March 2021, 21:00:00
CAMBRIDGE, Mass.–(BUSINESS WIRE)–AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company’s Chief Executive Officer (CEO), effective May 17, 2021. Dr. Brainard has served on AlloVir’s Board of Directors since April 2019, initially as a Board Observer, and as an Independent Director since July 2020. Dr. Brainard currently serves as Senior Vice President and Head of the Virology Therapeu
— Business Wire


AlloVir, Inc. (NASDAQ:ALVR) Insider Beek Jeroen B. Van Sells 5,932 Shares

Thursday, 4 March 2021, 14:27:15
AlloVir, Inc. (NASDAQ:ALVR) insider Beek Jeroen B. Van sold 5,932 shares of the firm’s stock in a transaction on Monday, March 1st. The stock was sold at an average price of $38.78, for a total value of $230,042.96. Following the completion of the sale, the insider now owns 489,830 shares of the company’s stock, valued […]
— Watchlist News


Insider Selling: AlloVir, Inc. (NASDAQ:ALVR) Director Sells 32,854 Shares of Stock

Thursday, 4 March 2021, 03:24:41
AlloVir, Inc. (NASDAQ:ALVR) Director Juan Vera sold 32,854 shares of the business’s stock in a transaction on Monday, March 1st. The shares were sold at an average price of $38.59, for a total transaction of $1,267,835.86. Following the completion of the transaction, the director now owns 2,392,194 shares of the company’s stock, valued at $92,314,766.46. […]
— Watchlist News


AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference – Stocks News Feed

Wednesday, 17 February 2021, 13:30:00
CAMBRIDGE, Mass.–(BUSINESS WIRE)–$ALVR #celltherapy–AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021 at 4:20 p.m. ET. The presentation will be available on the Investors & Press section of the AlloVir website at https://ir.allovir.com. An archived replay… Read More »AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference
— Stocks News Feed


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have ALVR available or trade one of the many other CFD stocks they have.
Risk warning: 71.2% of retail investor accounts lose money when trading CFDs with Capital.